 | • レポートコード：GIR-107A12479 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、123ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、分子診断がんのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。分子診断がんの種類別市場規模（薬理ゲノミクス診断、リキッドバイオプシー、その他）、用途別市場規模（呼吸器がん、消化器がん、泌尿器がん、循環器がん、運動器がん、生殖器がん、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・分子診断がんの市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Roche、Danaher、Siemens、Abbott Laboratories、ICON Plc、AstraZeneca、MDxHealth、Invitae、PlexBio、Thermo Fisher Scientific、Guardant Health、Biocartis、Bio-Techne、Merck、Foundation Medicine、10X Genomics、Biodesix、CytoTrack、GenomOncology、Luminex ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：薬理ゲノミクス診断、リキッドバイオプシー、その他 ・用途別分析2016年-2026年：呼吸器がん、消化器がん、泌尿器がん、循環器がん、運動器がん、生殖器がん、その他 ・分子診断がんの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・分子診断がんのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・分子診断がんのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・分子診断がんの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・分子診断がんの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Molecular Diagnostics Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Molecular Diagnostics Cancer size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Molecular Diagnostics Cancer market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Molecular Diagnostics Cancer market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Pharmacogenomic Diagnosis
Liquid Biopsy
Other
Market segment by Application, can be divided into
Respiratory Cancer
Cancer of Digestive System
Cancer of Urinary System
Cancer of Circulatory System
Motor System Cancer
Reproductive System Cancer
Other
Market segment by players, this report covers
Roche
Danaher
Siemens
Abbott Laboratories
ICON Plc
AstraZeneca
MDxHealth
Invitae
PlexBio
Thermo Fisher Scientific
Guardant Health
Biocartis
Bio-Techne
Merck
Foundation Medicine
10X Genomics
Biodesix
CytoTrack
GenomOncology
Luminex
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Molecular Diagnostics Cancer
1.2 Classification of Molecular Diagnostics Cancer by Type
1.2.1 Overview: Global Molecular Diagnostics Cancer Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Molecular Diagnostics Cancer Revenue Market Share by Type in 2020
1.2.3 Pharmacogenomic Diagnosis
1.2.4 Liquid Biopsy
1.2.5 Other
1.3 Global Molecular Diagnostics Cancer Market by Application
1.3.1 Overview: Global Molecular Diagnostics Cancer Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Respiratory Cancer
1.3.3 Cancer of Digestive System
1.3.4 Cancer of Urinary System
1.3.5 Cancer of Circulatory System
1.3.6 Motor System Cancer
1.3.7 Reproductive System Cancer
1.3.8 Other
1.4 Global Molecular Diagnostics Cancer Market Size & Forecast
1.5 Global Molecular Diagnostics Cancer Market Size and Forecast by Region
1.5.1 Global Molecular Diagnostics Cancer Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Molecular Diagnostics Cancer Market Size by Region, (2016-2021)
1.5.3 North America Molecular Diagnostics Cancer Market Size and Prospect (2016-2026)
1.5.4 Europe Molecular Diagnostics Cancer Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Molecular Diagnostics Cancer Market Size and Prospect (2016-2026)
1.5.6 South America Molecular Diagnostics Cancer Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Molecular Diagnostics Cancer Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Molecular Diagnostics Cancer Market Drivers
1.6.2 Molecular Diagnostics Cancer Market Restraints
1.6.3 Molecular Diagnostics Cancer Trends Analysis
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Molecular Diagnostics Cancer Product and Solutions
2.1.4 Roche Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Roche Recent Developments and Future Plans
2.2 Danaher
2.2.1 Danaher Details
2.2.2 Danaher Major Business
2.2.3 Danaher Molecular Diagnostics Cancer Product and Solutions
2.2.4 Danaher Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Danaher Recent Developments and Future Plans
2.3 Siemens
2.3.1 Siemens Details
2.3.2 Siemens Major Business
2.3.3 Siemens Molecular Diagnostics Cancer Product and Solutions
2.3.4 Siemens Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Siemens Recent Developments and Future Plans
2.4 Abbott Laboratories
2.4.1 Abbott Laboratories Details
2.4.2 Abbott Laboratories Major Business
2.4.3 Abbott Laboratories Molecular Diagnostics Cancer Product and Solutions
2.4.4 Abbott Laboratories Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Abbott Laboratories Recent Developments and Future Plans
2.5 ICON Plc
2.5.1 ICON Plc Details
2.5.2 ICON Plc Major Business
2.5.3 ICON Plc Molecular Diagnostics Cancer Product and Solutions
2.5.4 ICON Plc Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 ICON Plc Recent Developments and Future Plans
2.6 AstraZeneca
2.6.1 AstraZeneca Details
2.6.2 AstraZeneca Major Business
2.6.3 AstraZeneca Molecular Diagnostics Cancer Product and Solutions
2.6.4 AstraZeneca Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 AstraZeneca Recent Developments and Future Plans
2.7 MDxHealth
2.7.1 MDxHealth Details
2.7.2 MDxHealth Major Business
2.7.3 MDxHealth Molecular Diagnostics Cancer Product and Solutions
2.7.4 MDxHealth Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 MDxHealth Recent Developments and Future Plans
2.8 Invitae
2.8.1 Invitae Details
2.8.2 Invitae Major Business
2.8.3 Invitae Molecular Diagnostics Cancer Product and Solutions
2.8.4 Invitae Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Invitae Recent Developments and Future Plans
2.9 PlexBio
2.9.1 PlexBio Details
2.9.2 PlexBio Major Business
2.9.3 PlexBio Molecular Diagnostics Cancer Product and Solutions
2.9.4 PlexBio Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 PlexBio Recent Developments and Future Plans
2.10 Thermo Fisher Scientific
2.10.1 Thermo Fisher Scientific Details
2.10.2 Thermo Fisher Scientific Major Business
2.10.3 Thermo Fisher Scientific Molecular Diagnostics Cancer Product and Solutions
2.10.4 Thermo Fisher Scientific Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Thermo Fisher Scientific Recent Developments and Future Plans
2.11 Guardant Health
2.11.1 Guardant Health Details
2.11.2 Guardant Health Major Business
2.11.3 Guardant Health Molecular Diagnostics Cancer Product and Solutions
2.11.4 Guardant Health Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Guardant Health Recent Developments and Future Plans
2.12 Biocartis
2.12.1 Biocartis Details
2.12.2 Biocartis Major Business
2.12.3 Biocartis Molecular Diagnostics Cancer Product and Solutions
2.12.4 Biocartis Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Biocartis Recent Developments and Future Plans
2.13 Bio-Techne
2.13.1 Bio-Techne Details
2.13.2 Bio-Techne Major Business
2.13.3 Bio-Techne Molecular Diagnostics Cancer Product and Solutions
2.13.4 Bio-Techne Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Bio-Techne Recent Developments and Future Plans
2.14 Merck
2.14.1 Merck Details
2.14.2 Merck Major Business
2.14.3 Merck Molecular Diagnostics Cancer Product and Solutions
2.14.4 Merck Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Merck Recent Developments and Future Plans
2.15 Foundation Medicine
2.15.1 Foundation Medicine Details
2.15.2 Foundation Medicine Major Business
2.15.3 Foundation Medicine Molecular Diagnostics Cancer Product and Solutions
2.15.4 Foundation Medicine Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Foundation Medicine Recent Developments and Future Plans
2.16 10X Genomics
2.16.1 10X Genomics Details
2.16.2 10X Genomics Major Business
2.16.3 10X Genomics Molecular Diagnostics Cancer Product and Solutions
2.16.4 10X Genomics Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 10X Genomics Recent Developments and Future Plans
2.17 Biodesix
2.17.1 Biodesix Details
2.17.2 Biodesix Major Business
2.17.3 Biodesix Molecular Diagnostics Cancer Product and Solutions
2.17.4 Biodesix Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Biodesix Recent Developments and Future Plans
2.18 CytoTrack
2.18.1 CytoTrack Details
2.18.2 CytoTrack Major Business
2.18.3 CytoTrack Molecular Diagnostics Cancer Product and Solutions
2.18.4 CytoTrack Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 CytoTrack Recent Developments and Future Plans
2.19 GenomOncology
2.19.1 GenomOncology Details
2.19.2 GenomOncology Major Business
2.19.3 GenomOncology Molecular Diagnostics Cancer Product and Solutions
2.19.4 GenomOncology Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.19.5 GenomOncology Recent Developments and Future Plans
2.20 Luminex
2.20.1 Luminex Details
2.20.2 Luminex Major Business
2.20.3 Luminex Molecular Diagnostics Cancer Product and Solutions
2.20.4 Luminex Molecular Diagnostics Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.20.5 Luminex Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Molecular Diagnostics Cancer Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Molecular Diagnostics Cancer Players Market Share
3.2.2 Top 10 Molecular Diagnostics Cancer Players Market Share
3.2.3 Market Competition Trend
3.3 Molecular Diagnostics Cancer Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Molecular Diagnostics Cancer Revenue and Market Share by Type (2016-2021)
4.2 Global Molecular Diagnostics Cancer Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Molecular Diagnostics Cancer Revenue Market Share by Application (2016-2021)
5.2 Molecular Diagnostics Cancer Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Molecular Diagnostics Cancer Revenue by Type (2016-2026)
6.2 North America Molecular Diagnostics Cancer Revenue by Application (2016-2026)
6.3 North America Molecular Diagnostics Cancer Market Size by Country
6.3.1 North America Molecular Diagnostics Cancer Revenue by Country (2016-2026)
6.3.2 United States Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
6.3.3 Canada Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
6.3.4 Mexico Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Molecular Diagnostics Cancer Revenue by Type (2016-2026)
7.2 Europe Molecular Diagnostics Cancer Revenue by Application (2016-2026)
7.3 Europe Molecular Diagnostics Cancer Market Size by Country
7.3.1 Europe Molecular Diagnostics Cancer Revenue by Country (2016-2026)
7.3.2 Germany Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
7.3.3 France Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
7.3.5 Russia Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
7.3.6 Italy Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Molecular Diagnostics Cancer Revenue by Type (2016-2026)
8.2 Asia-Pacific Molecular Diagnostics Cancer Revenue by Application (2016-2026)
8.3 Asia-Pacific Molecular Diagnostics Cancer Market Size by Region
8.3.1 Asia-Pacific Molecular Diagnostics Cancer Revenue by Region (2016-2026)
8.3.2 China Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
8.3.3 Japan Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
8.3.4 South Korea Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
8.3.5 India Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
8.3.7 Australia Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Molecular Diagnostics Cancer Revenue by Type (2016-2026)
9.2 South America Molecular Diagnostics Cancer Revenue by Application (2016-2026)
9.3 South America Molecular Diagnostics Cancer Market Size by Country
9.3.1 South America Molecular Diagnostics Cancer Revenue by Country (2016-2026)
9.3.2 Brazil Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
9.3.3 Argentina Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Molecular Diagnostics Cancer Revenue by Type (2016-2026)
10.2 Middle East & Africa Molecular Diagnostics Cancer Revenue by Application (2016-2026)
10.3 Middle East & Africa Molecular Diagnostics Cancer Market Size by Country
10.3.1 Middle East & Africa Molecular Diagnostics Cancer Revenue by Country (2016-2026)
10.3.2 Turkey Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
10.3.4 UAE Molecular Diagnostics Cancer Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Molecular Diagnostics Cancer Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Molecular Diagnostics Cancer Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Molecular Diagnostics Cancer Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Molecular Diagnostics Cancer Revenue (USD Million) by Region (2016-2021)
Table 5. Global Molecular Diagnostics Cancer Revenue Market Share by Region (2021-2026)
Table 6. Roche Corporate Information, Head Office, and Major Competitors
Table 7. Roche Major Business
Table 8. Roche Molecular Diagnostics Cancer Product and Solutions
Table 9. Roche Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Danaher Corporate Information, Head Office, and Major Competitors
Table 11. Danaher Major Business
Table 12. Danaher Molecular Diagnostics Cancer Product and Solutions
Table 13. Danaher Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Siemens Corporate Information, Head Office, and Major Competitors
Table 15. Siemens Major Business
Table 16. Siemens Molecular Diagnostics Cancer Product and Solutions
Table 17. Siemens Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Abbott Laboratories Corporate Information, Head Office, and Major Competitors
Table 19. Abbott Laboratories Major Business
Table 20. Abbott Laboratories Molecular Diagnostics Cancer Product and Solutions
Table 21. Abbott Laboratories Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. ICON Plc Corporate Information, Head Office, and Major Competitors
Table 23. ICON Plc Major Business
Table 24. ICON Plc Molecular Diagnostics Cancer Product and Solutions
Table 25. ICON Plc Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 27. AstraZeneca Major Business
Table 28. AstraZeneca Molecular Diagnostics Cancer Product and Solutions
Table 29. AstraZeneca Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. MDxHealth Corporate Information, Head Office, and Major Competitors
Table 31. MDxHealth Major Business
Table 32. MDxHealth Molecular Diagnostics Cancer Product and Solutions
Table 33. MDxHealth Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Invitae Corporate Information, Head Office, and Major Competitors
Table 35. Invitae Major Business
Table 36. Invitae Molecular Diagnostics Cancer Product and Solutions
Table 37. Invitae Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. PlexBio Corporate Information, Head Office, and Major Competitors
Table 39. PlexBio Major Business
Table 40. PlexBio Molecular Diagnostics Cancer Product and Solutions
Table 41. PlexBio Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Thermo Fisher Scientific Corporate Information, Head Office, and Major Competitors
Table 43. Thermo Fisher Scientific Major Business
Table 44. Thermo Fisher Scientific Molecular Diagnostics Cancer Product and Solutions
Table 45. Thermo Fisher Scientific Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Guardant Health Corporate Information, Head Office, and Major Competitors
Table 47. Guardant Health Major Business
Table 48. Guardant Health Molecular Diagnostics Cancer Product and Solutions
Table 49. Guardant Health Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Biocartis Corporate Information, Head Office, and Major Competitors
Table 51. Biocartis Major Business
Table 52. Biocartis Molecular Diagnostics Cancer Product and Solutions
Table 53. Biocartis Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Bio-Techne Corporate Information, Head Office, and Major Competitors
Table 55. Bio-Techne Major Business
Table 56. Bio-Techne Molecular Diagnostics Cancer Product and Solutions
Table 57. Bio-Techne Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Merck Corporate Information, Head Office, and Major Competitors
Table 59. Merck Major Business
Table 60. Merck Molecular Diagnostics Cancer Product and Solutions
Table 61. Merck Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Foundation Medicine Corporate Information, Head Office, and Major Competitors
Table 63. Foundation Medicine Major Business
Table 64. Foundation Medicine Molecular Diagnostics Cancer Product and Solutions
Table 65. Foundation Medicine Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. 10X Genomics Corporate Information, Head Office, and Major Competitors
Table 67. 10X Genomics Major Business
Table 68. 10X Genomics Molecular Diagnostics Cancer Product and Solutions
Table 69. 10X Genomics Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Biodesix Corporate Information, Head Office, and Major Competitors
Table 71. Biodesix Major Business
Table 72. Biodesix Molecular Diagnostics Cancer Product and Solutions
Table 73. Biodesix Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. CytoTrack Corporate Information, Head Office, and Major Competitors
Table 75. CytoTrack Major Business
Table 76. CytoTrack Molecular Diagnostics Cancer Product and Solutions
Table 77. CytoTrack Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. GenomOncology Corporate Information, Head Office, and Major Competitors
Table 79. GenomOncology Major Business
Table 80. GenomOncology Molecular Diagnostics Cancer Product and Solutions
Table 81. GenomOncology Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 82. Luminex Corporate Information, Head Office, and Major Competitors
Table 83. Luminex Major Business
Table 84. Luminex Molecular Diagnostics Cancer Product and Solutions
Table 85. Luminex Molecular Diagnostics Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 86. Global Molecular Diagnostics Cancer Revenue (USD Million) by Players (2019-2021)
Table 87. Global Molecular Diagnostics Cancer Revenue Share by Players (2019-2021)
Table 88. Breakdown of Molecular Diagnostics Cancer by Company Type (Tier 1, Tier 2 and Tier 3)
Table 89. Molecular Diagnostics Cancer Players Head Office, Products and Services Provided
Table 90. Molecular Diagnostics Cancer Mergers & Acquisitions in the Past Five Years
Table 91. Molecular Diagnostics Cancer New Entrants and Expansion Plans
Table 92. Global Molecular Diagnostics Cancer Revenue (USD Million) by Type (2016-2021)
Table 93. Global Molecular Diagnostics Cancer Revenue Share by Type (2016-2021)
Table 94. Global Molecular Diagnostics Cancer Revenue Forecast by Type (2021-2026)
Table 95. Global Molecular Diagnostics Cancer Revenue by Application (2016-2021)
Table 96. Global Molecular Diagnostics Cancer Revenue Forecast by Application (2021-2026)
Table 97. North America Molecular Diagnostics Cancer Revenue by Type (2016-2021) & (USD Million)
Table 98. North America Molecular Diagnostics Cancer Revenue by Type (2021-2026) & (USD Million)
Table 99. North America Molecular Diagnostics Cancer Revenue by Application (2016-2021) & (USD Million)
Table 100. North America Molecular Diagnostics Cancer Revenue by Application (2021-2026) & (USD Million)
Table 101. North America Molecular Diagnostics Cancer Revenue by Country (2016-2021) & (USD Million)
Table 102. North America Molecular Diagnostics Cancer Revenue by Country (2021-2026) & (USD Million)
Table 103. Europe Molecular Diagnostics Cancer Revenue by Type (2016-2021) & (USD Million)
Table 104. Europe Molecular Diagnostics Cancer Revenue by Type (2021-2026) & (USD Million)
Table 105. Europe Molecular Diagnostics Cancer Revenue by Application (2016-2021) & (USD Million)
Table 106. Europe Molecular Diagnostics Cancer Revenue by Application (2021-2026) & (USD Million)
Table 107. Europe Molecular Diagnostics Cancer Revenue by Country (2016-2021) & (USD Million)
Table 108. Europe Molecular Diagnostics Cancer Revenue by Country (2021-2026) & (USD Million)
Table 109. Asia-Pacific Molecular Diagnostics Cancer Revenue by Type (2016-2021) & (USD Million)
Table 110. Asia-Pacific Molecular Diagnostics Cancer Revenue by Type (2021-2026) & (USD Million)
Table 111. Asia-Pacific Molecular Diagnostics Cancer Revenue by Application (2016-2021) & (USD Million)
Table 112. Asia-Pacific Molecular Diagnostics Cancer Revenue by Application (2021-2026) & (USD Million)
Table 113. Asia-Pacific Molecular Diagnostics Cancer Revenue by Region (2016-2021) & (USD Million)
Table 114. Asia-Pacific Molecular Diagnostics Cancer Revenue by Region (2021-2026) & (USD Million)
Table 115. South America Molecular Diagnostics Cancer Revenue by Type (2016-2021) & (USD Million)
Table 116. South America Molecular Diagnostics Cancer Revenue by Type (2021-2026) & (USD Million)
Table 117. South America Molecular Diagnostics Cancer Revenue by Application (2016-2021) & (USD Million)
Table 118. South America Molecular Diagnostics Cancer Revenue by Application (2021-2026) & (USD Million)
Table 119. South America Molecular Diagnostics Cancer Revenue by Country (2016-2021) & (USD Million)
Table 120. South America Molecular Diagnostics Cancer Revenue by Country (2021-2026) & (USD Million)
Table 121. Middle East & Africa Molecular Diagnostics Cancer Revenue by Type (2016-2021) & (USD Million)
Table 122. Middle East & Africa Molecular Diagnostics Cancer Revenue by Type (2021-2026) & (USD Million)
Table 123. Middle East & Africa Molecular Diagnostics Cancer Revenue by Application (2016-2021) & (USD Million)
Table 124. Middle East & Africa Molecular Diagnostics Cancer Revenue by Application (2021-2026) & (USD Million)
Table 125. Middle East & Africa Molecular Diagnostics Cancer Revenue by Country (2016-2021) & (USD Million)
Table 126. Middle East & Africa Molecular Diagnostics Cancer Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Molecular Diagnostics Cancer Picture
Figure 2. Global Molecular Diagnostics Cancer Revenue Market Share by Type in 2020
Figure 3. Pharmacogenomic Diagnosis
Figure 4. Liquid Biopsy
Figure 5. Other
Figure 6. Molecular Diagnostics Cancer Revenue Market Share by Application in 2020
Figure 7. Respiratory Cancer Picture
Figure 8. Cancer of Digestive System Picture
Figure 9. Cancer of Urinary System Picture
Figure 10. Cancer of Circulatory System Picture
Figure 11. Motor System Cancer Picture
Figure 12. Reproductive System Cancer Picture
Figure 13. Other Picture
Figure 14. Global Molecular Diagnostics Cancer Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 15. Global Molecular Diagnostics Cancer Revenue and Forecast (2016-2026) & (USD Million)
Figure 16. Global Molecular Diagnostics Cancer Revenue Market Share by Region (2016-2026)
Figure 17. Global Molecular Diagnostics Cancer Revenue Market Share by Region in 2020
Figure 18. North America Molecular Diagnostics Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Europe Molecular Diagnostics Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Asia-Pacific Molecular Diagnostics Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. South America Molecular Diagnostics Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Middle East and Africa Molecular Diagnostics Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Molecular Diagnostics Cancer Market Drivers
Figure 24. Molecular Diagnostics Cancer Market Restraints
Figure 25. Molecular Diagnostics Cancer Market Trends
Figure 26. Roche Recent Developments and Future Plans
Figure 27. Danaher Recent Developments and Future Plans
Figure 28. Siemens Recent Developments and Future Plans
Figure 29. Abbott Laboratories Recent Developments and Future Plans
Figure 30. ICON Plc Recent Developments and Future Plans
Figure 31. AstraZeneca Recent Developments and Future Plans
Figure 32. MDxHealth Recent Developments and Future Plans
Figure 33. Invitae Recent Developments and Future Plans
Figure 34. PlexBio Recent Developments and Future Plans
Figure 35. Thermo Fisher Scientific Recent Developments and Future Plans
Figure 36. Guardant Health Recent Developments and Future Plans
Figure 37. Biocartis Recent Developments and Future Plans
Figure 38. Bio-Techne Recent Developments and Future Plans
Figure 39. Merck Recent Developments and Future Plans
Figure 40. Foundation Medicine Recent Developments and Future Plans
Figure 41. 10X Genomics Recent Developments and Future Plans
Figure 42. Biodesix Recent Developments and Future Plans
Figure 43. CytoTrack Recent Developments and Future Plans
Figure 44. GenomOncology Recent Developments and Future Plans
Figure 45. Luminex Recent Developments and Future Plans
Figure 46. Global Molecular Diagnostics Cancer Revenue Share by Players in 2020
Figure 47. Molecular Diagnostics Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 48. Global Top 3 Players Molecular Diagnostics Cancer Revenue Market Share in 2020
Figure 49. Global Top 10 Players Molecular Diagnostics Cancer Revenue Market Share in 2020
Figure 50. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 51. Global Molecular Diagnostics Cancer Revenue Share by Type in 2020
Figure 52. Global Molecular Diagnostics Cancer Market Share Forecast by Type (2021-2026)
Figure 53. Global Molecular Diagnostics Cancer Revenue Share by Application in 2020
Figure 54. Global Molecular Diagnostics Cancer Market Share Forecast by Application (2021-2026)
Figure 55. North America Molecular Diagnostics Cancer Sales Market Share by Type (2016-2026)
Figure 56. North America Molecular Diagnostics Cancer Sales Market Share by Application (2016-2026)
Figure 57. North America Molecular Diagnostics Cancer Revenue Market Share by Country (2016-2026)
Figure 58. United States Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Canada Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Mexico Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Europe Molecular Diagnostics Cancer Sales Market Share by Type (2016-2026)
Figure 62. Europe Molecular Diagnostics Cancer Sales Market Share by Application (2016-2026)
Figure 63. Europe Molecular Diagnostics Cancer Revenue Market Share by Country (2016-2026)
Figure 64. Germany Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. France Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. United Kingdom Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Russia Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Italy Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Asia-Pacific Molecular Diagnostics Cancer Sales Market Share by Type (2016-2026)
Figure 70. Asia-Pacific Molecular Diagnostics Cancer Sales Market Share by Application (2016-2026)
Figure 71. Asia-Pacific Molecular Diagnostics Cancer Revenue Market Share by Region (2016-2026)
Figure 72. China Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Japan Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. South Korea Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. India Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Southeast Asia Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Australia Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. South America Molecular Diagnostics Cancer Sales Market Share by Type (2016-2026)
Figure 79. South America Molecular Diagnostics Cancer Sales Market Share by Application (2016-2026)
Figure 80. South America Molecular Diagnostics Cancer Revenue Market Share by Country (2016-2026)
Figure 81. Brazil Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 82. Argentina Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 83. Middle East and Africa Molecular Diagnostics Cancer Sales Market Share by Type (2016-2026)
Figure 84. Middle East and Africa Molecular Diagnostics Cancer Sales Market Share by Application (2016-2026)
Figure 85. Middle East and Africa Molecular Diagnostics Cancer Revenue Market Share by Country (2016-2026)
Figure 86. Turkey Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 87. Saudi Arabia Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 88. UAE Molecular Diagnostics Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 89. Methodology
Figure 90. Research Process and Data Source
世界の腫瘍学系分子診断市場予測（～2024年） Molecular diagnosis of tumor refers to the molecular biological diagnosis technology with nucleic acid or protein as the core, which is an important method for early diagnosis of tumor. Scope of the Report: The worldwide market for Oncology Based Molecular Diagnostics is expected to grow at a CAGR o…- 世界の非侵襲的がん診断市場 2021：企業別、地域別、種類・用途別 The Non-invasive Cancer Diagnosis market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade r…
- 世界の腎臓がん治療・診断市場 2021：企業別、地域別、種類・用途別 The Kidney Cancer Therapeutics and Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimiza…
- 分子診断（MDx）の世界市場 2019年版：種類別（非侵襲的出生前検査（NIPT）、診断とともに、液体生検、その他の分子診断）、用途別（心血管、神経学、胃腸病学、感染症、腫瘍学、その他） Scope of the Report: The global Molecular Diagnosis (MDx) market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in China,…
- ポイントオブケア（POC）分子診断の世界市場… Scope of the Report: The global Point-of-Care Molecular Diagnostics market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially…